Identification of potential therapeutic drugs targeting core genes for systemic lupus erythematosus (SLE) and coexisting COVID‐19: Insights from bioinformatic analyses

Abstract

Abstract Objective Systemic lupus erythematosus (SLE) patients are at risk during the COVID‐19 pandemic, yet the underlying molecular mechanisms remain incompletely understood. This study sought to analyze the potential molecular connections between COVID‐19 and SLE, employing a bioinformatics approach to identify effective drugs for both conditions. Methods The data sets GSE100163 and GSE183071 were utilized to determine share differentially expressed genes (DEGs). These DEGs were later analyzed by various bioinformatic methods, including functional enrichment, protein–protein interaction (PPI) network analysis, regulatory network construction, and gene–drug interaction construction. Results A total of 50 common DEGs were found between COVID‐19 and SLE. Gene ontology (GO) functional annotation revealed that “immune response,” “innate immune response,” “plasma membrane,” and “protein binding” were most enriched in. Additionally, the pathways that were enriched include “Th1 and Th2 cell differentiation.” The study identified 48 genes/nodes enriched with 292 edges in the PPI network, of which the top 10 hub genes were CD4, IL7R, CD3E, CD5, CD247, KLRB1, CD40LG, CD7, CR2, and GZMK. Furthermore, the study found 48 transcription factors and 8 microRNAs regulating these hub genes. Finally, four drugs namely ibalizumab (targeted to CD4), blinatumomab (targeted to CD3E), muromonab‐CD3 (targeted to CD3E), and catumaxomab (targeted to CD3E) were found in gene–drug interaction. Conclusion Four possible drugs that targeted two specific genes, which may be beneficial for COVID‐19 patients with SLE.

Keywords

• bioinformatic
• differentially expressed genes
• severe coronavirus disease 2019 (COVID‐19)
• systemic lupus erythematosus (SLE)
• targeted drugs